Chapter 1. Introduction
1.1.Research Objective
1.2.Scope of the Study
1.3.Definition
Chapter 2. Research Methodology
2.1.Research Approach
2.2.Data Sources
2.3.Assumptions & Limitations
Chapter 3. Executive Summary
3.1.Market Snapshot
Chapter 4. Market Variables and Scope
4.1.Introduction
4.2.Market Classification and Scope
4.3.Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Therapeutic Area Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market
5.1.COVID-19 Landscape: Formulation Development Outsourcing Industry Impact
5.2.COVID 19 - Impact Assessment for the Industry
5.3.COVID 19 Impact: Global Major Government Policy
5.4.Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1.Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2.Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Formulation Development Outsourcing Market, By Service
8.1.Formulation Development Outsourcing Market, by Service Type, 2022-2030
8.1.1. Preformulation
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Formulation Development
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Formulation Development Outsourcing Market, By Formulation
9.1.Formulation Development Outsourcing Market, by Formulation, 2022-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Injectable
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Topical
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10.Global Formulation Development Outsourcing Market, By Therapeutic Area Channel
10.1.Formulation Development Outsourcing Market, by Therapeutic Area Channel, 2022-2030
10.1.1.Oncology
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2.Infectious Diseases
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3.Neurology
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4.Hematology
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5.Respiratory
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6.Cardiovascular
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7.Dermatology
10.1.7.1. Market Revenue and Forecast (2017-2030)
10.1.8.Others
10.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 11.Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast
11.1.North America
11.1.1.Market Revenue and Forecast, by Service (2017-2030)
11.1.2.Market Revenue and Forecast, by Formulation (2017-2030)
11.1.3.Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.1.4.U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.1.5.Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.2.Europe
11.2.1.Market Revenue and Forecast, by Service (2017-2030)
11.2.2.Market Revenue and Forecast, by Formulation (2017-2030)
11.2.3.Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.2.4.UK
11.2.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.2.5.Germany
11.2.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.2.6.France
11.2.6.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.2.7.Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.3.APAC
11.3.1.Market Revenue and Forecast, by Service (2017-2030)
11.3.2.Market Revenue and Forecast, by Formulation (2017-2030)
11.3.3.Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.3.4.India
11.3.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.3.5.China
11.3.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.3.6.Japan
11.3.6.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.3.7.Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.4.MEA
11.4.1.Market Revenue and Forecast, by Service (2017-2030)
11.4.2.Market Revenue and Forecast, by Formulation (2017-2030)
11.4.3.Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.4.4.GCC
11.4.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.4.5.North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.4.6.South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.4.7.Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.5.Latin America
11.5.1.Market Revenue and Forecast, by Service (2017-2030)
11.5.2.Market Revenue and Forecast, by Formulation (2017-2030)
11.5.3.Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.5.4.Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
11.5.5.Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Formulation (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Therapeutic Area Channel (2017-2030)
Chapter 12.Company Profiles
12.1.SGS S.A.
12.1.1.Company Overview
12.1.2.Product offerings
12.1.3.Financial Performance
12.1.4.Recent Initiatives
12.2.Intertek Group plc
12.2.1.Company Overview
12.2.2.Product offerings
12.2.3.Financial Performance
12.2.4.Recent Initiatives
12.3.Recipharm
12.3.1.Company Overview
12.3.2.Product offerings
12.3.3.Financial Performance
12.3.4.Recent Initiatives
12.4.Lonza
12.4.1.Company Overview
12.4.2.Product offerings
12.4.3.Financial Performance
12.4.4.Recent Initiatives
12.5.Charles River Laboratories International, Inc.
12.5.1.Company Overview
12.5.2.Product offerings
12.5.3.Financial Performance
12.5.4.Recent Initiatives
12.6.Eurofins Scientific SE
12.6.1.Company Overview
12.6.2.Product offerings
12.6.3.Financial Performance
12.6.4.Recent Initiatives
12.7.Element
12.7.1.Company Overview
12.7.2.Product offerings
12.7.3.Financial Performance
12.7.4.Recent Initiatives
12.8.Labcorp
12.8.1.Company Overview
12.8.2.Product offerings
12.8.3.Financial Performance
12.8.4.Recent Initiatives
12.9.Thermo Fisher Scientific, Inc. (Patheon)
12.9.1.Company Overview
12.9.2.Product offerings
12.9.3.Financial Performance
12.9.4.Recent Initiatives
12.10.Catalent Inc.
12.10.1. Company Overview
12.10.2. Product offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13.Research Methodology
13.1.Primary Research
13.2.Secondary Research
13.3.Assumptions
Chapter 14.Appendix
14.1.About Us
14.2.Glossary of Terms